About this archived opportunity

Cooperative agreements under this Alzheimer"s Disease Programs Initiative (ADPI) Notice of Funding Opportunity (NOFO) are intended to support and promote the development and implementation of dementia-capable home and community-based service (HCBS) systems in Indian Country. The Dementia Capability in Indian Country program is intended to support federally recognized tribes, tribal organizations and/or consortiums representing federally recognized tribes in these targeted activities. The dementia-capable systems resulting from activities under this program are expected to provide quality, strengths-based services and supports that help people living with dementia and their caregivers remain independent and safe in their communities. There are two application options contained in this single NOFO: Grants to Tribes and Tribal Entities that have previously received ADPI grants (Option A) and Grants to Tribes and Tribal Entities that are new to the ADPI program (Option B). Applicants for the 36-month Dementia in Indian Country cooperative agreement are those entities that are presently responsible for the provision of and actively providing home and community services in tribal communities (i.e. tribes, tribal organizations and/or consortiums representing federally recognized tribes). Applicants for Option A will propose the ways in which they will expand on their previously funded ADPI programs (this grant program is not intended to sustain previously funded ADPI activities) and applicants under option B will propose to enhance existing service systems with dementia services, resulting in the provision of services to Tribal Elders and their caregivers through a dementia-capable system. Responsive applications will demonstrate tribal leadership support and the authority to conduct the activities proposed in their application.

Related opportunities

• Addressing Dementia in Tribal and Urban Indian Communities: CAReS ProgramIndian Health Service·Closes in 24 days·Up to $750K
• Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)National Institutes of Health·Closes Nov 2026
• DoW Alzheimer’s Transforming Diagnosis AwardDefense Health Agency Contracting Activity - DHACA·Closes in 44 days
• Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)National Institutes of Health·Closes Nov 2027·Up to $1.5M